基于生物标志物和通用策略治疗晚期子宫内膜癌的成本效益
本研究采用马尔可夫成本效用模型,从第三方支付者视角比较了针对新诊断III-IV期子宫内膜癌的化疗、通用免疫治疗和靶向免疫治疗策略的成本效益。结果显示,所有靶向免疫治疗策略在非西班牙裔黑人和非西班牙裔白人中均比单纯化疗具有成本效益,而通用免疫治疗从未具有成本效益;针对dMMR的dostarlimab联合针对HER2阳性浆液性癌和癌肉瘤的曲妥珠单抗是最具成本效益的策略,ICER为119,945美元/QALY。作者认为应考虑纳入HER2和MMR检测的个性化治疗策略,以优化成本效益和公平性。
要点
- 靶向免疫治疗策略在非西班牙裔黑人和白人中均比单纯化疗具有成本效益。
- 通用免疫治疗策略在任何人群中均不具有成本效益。
- dostarlimab用于dMMR联合曲妥珠单抗用于HER2阳性浆液性癌和癌肉瘤是最具成本效益的策略,ICER为119,945美元/QALY。
核心结论
- 作者认为,应考虑采用纳入HER2和MMR检测的个性化治疗策略,以优化成本效益和公平性。
研究设计与样本
- 研究采用基于马尔可夫的成本效用模型,从第三方支付者视角进行分析。
- 比较了新诊断III-IV期子宫内膜癌的化疗、3种通用免疫治疗策略和3种靶向免疫治疗策略。
- 基础病例分析为10,000次运行的微观模拟,并进行了20,000次试验的蒙特卡洛概率敏感性分析。
- 成本(2024年美元)、效用值和临床估计值来源于已发表文献和国家癌症数据库。
- 成本效益评估采用增量成本效益比(ICER),支付意愿阈值为150,000美元/质量调整生命年(QALY)。
主要发现
- 在非西班牙裔黑人和非西班牙裔白人中,所有靶向免疫治疗策略与单纯化疗相比均具有成本效益,而通用免疫治疗从未具有成本效益。
- 靶向策略在非西班牙裔黑人中的成本效益高于非西班牙裔白人。
- 与化疗相比,dostarlimab用于dMMR联合曲妥珠单抗用于HER2阳性浆液性癌和癌肉瘤是最具成本效益的策略,ICER为119,945美元/QALY。
- 在敏感性分析中,假设治疗获益持续时间更长可导致更低的ICER。
临床怎么用
- 作者认为,应考虑采用纳入HER2和MMR检测的个性化治疗策略,以优化成本效益和公平性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare cost-effectiveness of targeted therapeutic strategies for non-Hispanic Black (NHB) and non-Hispanic White (NHB) patients with newly diagnosed, advanced-stage endometrial cancer. METHODS: A Markov-based cost-utility model using a third-party payer perspective compared concurrent and maintenance treatment strategies incorporating dostarlimab and trastuzumab for newly diagnosed stage III-IV endometrial cancer: chemotherapy alone; 3 universal immunotherapy strategies (universal concurrent and maintenance dostarlimab +/- trastuzumab for HER2/neu-positive serous and/or carcinosarcomas); and 3 targeted immunotherapy strategies (dostarlimab for mismatch repair deficient (dMMR) tumors +/- trastuzumab for HER2/neu positive serous and/or carcinosarcomas). Costs (2024 USD), utilities, and clinical estimates were derived from published literature and the National Cancer Database. The base case analysis was a microsimulation with 10,000 runs, accompanied by a Monte Carlo probabilistic sensitivity analysis with 20,000 trials. Cost-effectiveness was assessed using incremental cost-effectiveness ratios (ICERs) with a willingness-to-pay threshold of $150,000/quality-adjusted life year (QALY). We performed one-way and two-way sensitivity analyses on key parameters and analyses stratified by race/ethnicity. RESULTS: All targeted immunotherapy strategies were cost-effective compared to chemotherapy alone in both NHB and NHW, while universal immunotherapy was never cost-effective. Targeted strategies were more cost-effective in NHB than NHW. Targeted dostarlimab for dMMR plus trastuzumab for HER2 serous and carcinosarcomas was the most cost-effective strategy compared to chemotherapy, with an ICER of $119,945/QALY. In sensitivity analysis, assuming longer durations of treatment benefit resulted in lower ICERs. CONCLUSIONS: Personalized treatment strategies incorporating HER2 and MMR testing should be considered to optimize both cost-effectiveness and equity in care.
引用
- Bashi A, Chen L, Rouse K, et al. Cost-effectiveness of biomarker-based and universal strategies for the treatment of advanced-stage endometrial cancer. Gynecol Oncol. 2025. PMID: 41187375. doi:10.1016/j.ygyno.2025.09.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。